Tag: control

VANCOUVER, BC, June 11, 2026 /CNW/ - GoldMining Inc. (TSX: GOLD) (NYSE American: GLDG) (the "Company" or "GoldMining") is pleased to announce the results of a...

VANCOUVER, BC, June 11, 2026 /PRNewswire/ - GoldMining Inc. (TSX: GOLD) (NYSE American: GLDG) (the "Company" or "GoldMining") is pleased to announce the results of a...

XING Mobility unveils IMMERSIO™ Matrix, an immersion-cooled marine battery system delivering twice the energy density and 3C discharge for electric vessels

Automotive tier 2 zinc die-casting manufacturer adopts cloud-based MES, QMS, EDI and analytics to provide real-time visibility, traceability and quality across a new greenfield...

Now among the fastest-scaling monopolar RF devices worldwide, XERF™ has more than tripled its pace of adoption in recent months with Asia-Pacific and North...

Patients in the IMAAVY 30 mg/kg treatment groupa achieved statistically significant durable hemoglobin responseb, with mean hemoglobin improvement of at least 1 g/dL as...

The share of C-suite executives identifying AI-related conduct risks as a top material risk has jumped from 16% over the past three years to...

CALGARY, AB, June 10, 2026 /PRNewswire/ - Horizon Petroleum Ltd. ("Horizon" or the "Company") (TSXV: HPL) (FRA: HPM) (Tradegate: HPM) is pleased to announce the...

LOS ANGELES, June 10, 2026 /PRNewswire/ -- Prostate pleasure may be one of the few forms of pleasure men can uniquely experience. But why...

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

Defiance ETFs to Launch SPCU, The 2X SpaceX ETF, as the SpaceX (SPCX) IPO Nears